Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pivotal phase III trial of RP 5063 in patients with schizophrenia.

Trial Profile

Pivotal phase III trial of RP 5063 in patients with schizophrenia.

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brilaroxazine (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Reviva Pharmaceuticals
  • Most Recent Events

    • 06 Nov 2013 Study title is not official. MR 9155878 refers to multiple pivotal phase III trials, but there is no way of distinguishing them. Disease assumed.
    • 06 Nov 2013 New trial record
    • 05 Nov 2013 Initiation of pivotal phase III trials is planned for early 2014, according to a Reviva Pharmaceuticals media release. The company has received guidance from the FDA for the phase III development plan of RP 5063.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top